THE EFFECT OF LIPOFLAVON ® ON BLOOD GLUCOSE LEVEL AND VASCULAR DYSFUNCTION IN DIABETIC RATS

Authors

  • Klymenko K. I. SI «Institute of Pharmacology and Toxicology of the NAMS of Ukraine», Kyiv
  • Zelenskiy D. S. SI «Institute of Pharmacology and Toxicology of the NAMS of Ukraine», Kyiv
  • Soloviev A. I. SI «Institute of Pharmacology and Toxicology of the NAMS of Ukraine», Kyiv

DOI:

https://doi.org/10.21856/j-PEP.2013.4.05

Keywords:

experimental diabetes, aorta, vascular dysfunction, endothelium-dependent vasodilatation, K-current, Lipoflavon, Quercetin

Abstract

In an experiment in rats with streptozotocin-induced diabetic found that long intraperitoneal administration of a Lipoflavon®at a concentration of 1.4 mg/kg (in the recalculation on the active ingredient Quercetin) leads to a decrease in blood glucose levels, contributes to increase the total effluent K+-current to isolated smooth muscle cells, as well as normalization of endothelium-dependent vasodilation of isolated aortic ring segments. At the same time Lipoflavon®eliminates oscillations of vascular tone in diabetic animals and has a positive effect on Ca2+ — sensitization of myofilaments.

References

Atkinson MA, Maclaren NK. N Engl J Med 1994; 331:1428–1436.

Fowler MJ. Clin Diabetes 2008; 26(2):77–82.

Jackson WF. Hypertension 2000; 35(2):173–178.

Ding H, Triggle CR. Pßugers Archiv 2010; 459:977–994.

Naser N, Januszewski AS, Brown BE, et al. Front Physiol 2013; 4(38).

Munaron L, Fiorio Pla A. Cur Med Chem 2009; 16:4691–4703.

Soloviev AI, Bershtein SA. J Hypertension 1992; 10(2):131–136.

Annapurna A, Reddy CS, Akondi RB, Rao SR. J Pharm Pharmacol 2009; 61(10):1365–74.

Stefanov AB, Solov’ev AI. Doklady AN SSSR 1983; 273(1):227–230.

Grynkiewicz G, Poenie GM, Tsien RY. J Biol Chem 1985; 260:3440–3450.

Blatter LA, Wier WG. Biophys J 1990; 58:1491–1499.

Vessal M, Hemmati M, Vasei M. Comp Biochem Physiol Comp Pharmacol Toxicol 2003; 135:357–364.

Bardy G, Virsolvy A, Quignard JF, et al. Br J Pharmacol 2013; 169(5):1102–1113.

Hartge MM, Kintscher U, Unger T. Endocrinol Metab Clin North Am 2006; 35:551–560.

Brownlee M. Diabetes 2005; 54:1615–1625.

Oishi H, Schuster A, Lamboley M. Life Sci 2002; 71(19):2239–2248.

Soloviev A, Tishkin S, Kyrychenko S. Acta Physiologica Sinica 2009; 63(3):201–210.

Klymenko KI, Novohac’ka TV, Kizub IV, Solovjov AI. Farmakologija ta Likars’ka Toksykologija 2012; 5(30):31–36.

Wang YJ, Lin MW, Wu SN, Sung RJ. Biochem Pharmacol 2007; 73(9):1347–1357.

Romero M, Jiménez R, Sánchez M, et al. J Atherosclerosis 2009; 202(1): 58–67.

Downloads

Published

2013-12-20

How to Cite

Klymenko, K. I., Zelenskiy, D. S., & Soloviev, A. I. (2013). THE EFFECT OF LIPOFLAVON ® ON BLOOD GLUCOSE LEVEL AND VASCULAR DYSFUNCTION IN DIABETIC RATS. Problems of Endocrine Pathology, 46(4), 39-46. https://doi.org/10.21856/j-PEP.2013.4.05